AstraZeneca settles with Ranbaxy to stave off generic Nexium launch
AstraZeneca settled a patent dispute with Ranbaxy, which had threatened an "at risk" early generic launch against AstraZeneca's $5.5 billion drug Nexium.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.